Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMDW 57 5-Year RORE % is 0.00 as of Jun. 2026. GuruFocus rates BTMDW with a GF Score™ of 57/100. The stock has 2 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Biote ranks worse than 89.86% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Biote does not have enough data to calculate 5-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Biote 5-Year RORE % Related Terms
Biote 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Biote's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTMDW vs DCGO, PIII, CCEL: 5-Year RORE % Comparison
For the Medical Care Facilities subindustry, Biote's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote 5-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Biote's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 5-year before.
Biote (BTMDW) has a 5-Year RORE % of 0.00 as of Jun. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #461 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 89.9%.
Is Biote's 5-Year RORE % too high?
Biote's current 5-Year RORE % is 0.00. Based on the distribution chart, Biote ranks #461 out of 513 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Biote has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Biote's 5-Year RORE % compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #461 out of 513 companies for 5-Year RORE %. This places Biote in the lower half of its industry. The industry median 5-Year RORE % is 2.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Healthcare Providers & Services company?
The median 5-Year RORE % among Healthcare Providers & Services companies is 2.24, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median 5-Year RORE % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current 5-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Biote (BTMDW) has a current 5-Year RORE % of 0.00. The current 5-Year RORE % is 0.00. Biote's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Biote (BTMDW), the current 5-Year RORE % is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
57GF Score
Get the complete analysis for BTMDW
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMDW has been successfully added to your 
